ELUDE Trademark

Trademark Overview


On Wednesday, June 22, 2022, a trademark application was filed for ELUDE with the United States Patent and Trademark Office. The USPTO has given the ELUDE trademark a serial number of 97471499. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, July 2, 2024. This trademark is owned by GentiBio, Inc.. The ELUDE trademark is filed in the Treatment & Processing of Materials Services, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacture of pharmaceuticals for others; Custom manufacturing of biological cells; consultation in the field of custom manufacture of pharmaceuticals and biological cells

Gene therapy products, namely, engineered cell platforms for immunotherapy purposes; Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders and allergic diseases and disorders

Scientific research; Pharmaceutical research; Medical research; Engineering of biological cells; genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering
elude

General Information


Serial Number97471499
Word MarkELUDE
Filing DateWednesday, June 22, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, July 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 9, 2023

Trademark Statements


Goods and ServicesCustom manufacture of pharmaceuticals for others; Custom manufacturing of biological cells; consultation in the field of custom manufacture of pharmaceuticals and biological cells
Goods and ServicesGene therapy products, namely, engineered cell platforms for immunotherapy purposes; Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders and allergic diseases and disorders
Goods and ServicesScientific research; Pharmaceutical research; Medical research; Engineering of biological cells; genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering

Classification Information


International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateMonday, April 3, 2023
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 12, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, April 3, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGentiBio, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Party NameGentiBio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Trademark Events


Event DateEvent Description
Tuesday, July 12, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, June 25, 2022NEW APPLICATION ENTERED
Sunday, April 2, 2023ASSIGNED TO EXAMINER
Monday, April 3, 2023EXAMINERS AMENDMENT -WRITTEN
Monday, April 3, 2023EXAMINERS AMENDMENT E-MAILED
Monday, April 3, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, April 3, 2023EXAMINER'S AMENDMENT ENTERED
Monday, April 3, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 9, 2023PUBLISHED FOR OPPOSITION
Thursday, January 4, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, April 19, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 9, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 4, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 4, 2024SOU EXTENSION 1 FILED
Thursday, January 4, 2024SOU EXTENSION 1 GRANTED
Saturday, January 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 2, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 3, 2024SOU EXTENSION 2 FILED
Wednesday, July 3, 2024SOU EXTENSION 2 GRANTED